What level of risk should asymptomatic participants accept (or be allowed to accept) to help develop treatments for themselves or for others who are currently infected or might be in the future? Given different societal norms in different countries, will international regulators collaborate and share information to facilitate efficient approvals? And if not, can or should trial designs be altered, and what are the implications of such changes? Should some patient populations, e.g. the elderly, be asked or be willing to take higher risks to help accelerate the availability of new medicines?
...more
